Erschienen in:
12.11.2018 | ASO Author Reflections
ASO Author Reflections: Implementing a Program of Talimogene laherparepvec
verfasst von:
Frances Collichio, MD
Erschienen in:
Annals of Surgical Oncology
|
Sonderheft 3/2018
Einloggen, um Zugang zu erhalten
Excerpt
Oncolytic viral therapies have unique properties and methods of administration (intralesional, intravesical, intracranial, intracutaneous). Talimogene laherparevec (TVEC) was approved for the treatment of locally advanced melanoma in October 2015.
1 As biologic products, oncolytic viral treatments require unique safety and expertise to administer.
2 Pharmacy needs expertise in the process of order entry and product preparation. Facilities need freezers that can store TVEC at − 70 to –90 °C until immediately prior to use. Trained providers need to recognize unique procedural and tumor-related factors. Selected patients need to have no evidence of underlying immunodeficiency. Nurses need to know their role in the clinic, including how to handle the product, provide premedication, and instruct the patient before discharge. Pseudoprogression is common in the field of immuno-oncology (I/O) and with TVEC.
3,4 Because progression can take place before response, it can be difficult to determine when to stop treatment.
4 …
